Rodent models of stroke limitations: What can we learn from recent clinical trials of thrombolysis?

Archives of Neurology

Volumn 53, Issue 10, 1996, Pages 1067-1070

  Grotta, James ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CLOT LYSIS; BRAIN ISCHEMIA; DISEASE MODEL; HEALTH CARE; NONHUMAN; PATIENT CARE; PRIORITY JOURNAL; STROKE;

EID: 0029840025     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.1996.00550100153025     Document Type: Article

References (25)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
2. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. JAMA. 1995;274:1017-1025.
3. Wiebers DO, Adams HP Jr, Whisnant JP. Animal models of stroke: are they relevant to human disease? Stroke. 1990;21:1-3.
4. Zivin JA, Grotta JC. Animal stroke models: they are relevant to human disease. Stroke. 1990;21: 981-983.
5. Grotta J. The current status of neuronal protective therapy: why have all neuronal protective drugs worked in animals but none so far in stroke patients. Cerebrovasc Dis. 1994;4:115-120.
6. Grotta J. Why do all drugs work in animals but none in stroke patients? J Intern Med. 1995; 237:89-94.
7. Yang G, Betz L. Reperfusion-induced injury to the blood-brain barrier after middle cerebral artery occlusion in rats. Stroke. 1994;25:1658-1665.
8. Jones TH, Morawetz RB, Crowell RM, et al. Thresholds of focal cerebral ischemia in awake monkeys. J Neurosurg. 1981;54:773-782.
9. Ginsberg MD. Neuroprotection in brain ischemia, I: an update. Neuroscientist. 1995;1:95-103.
10. Ginsberg MD. Neuroprotection in brain ischemia, 2: an update. Neuroscientist. 1995;1:164-175.
11. Bullock R, Zauner A, Woodward J, Young HF. Massive persistent release of excitatory amino acids following human occlusive stroke. Stroke 1995;26:2187-2189.
12. Petito CK, Feldmann E, Pulsinelli WA, Plum F. Delayed hippocampal damage in humans following cardiorespiratory arrest. Neurology. 1987; 37:1281-1286.
13. The International Nimodipine Study Group. Metaanalysis of nimodipine trials in acute ischemic stroke. Stroke. 1992;23:148. Abstract.
14. Lenzi GL, Grigoletto F, Gent M, et al, and the Early Stroke Trial Group. Early treatment of stroke with monosialoganglioside GM-I: efficacy and safety results of the early stroke trial. Stroke. 1994; 25:1552-1558.
15. Brott TG, Haley EC Jr, Levy DE, et al. Urgent therapy for stroke, part I: pilot study of tissue plasminogen activator administered within 90 minutes. Stroke. 1992;23:632-640.
16. Haley EC Jr, Levy DE, Brott TG, et al. Urgent therapy for stroke, part 2: pilot study of tissue plasminogen activator administered 91-180 minutes from onset. Stroke. 1992;23:641-645.
17. del Zoppo GJ, Poeck K, Pessin MS, et al. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol. 1992; 32:78-97.
18. Mori E, Yoneda Y, Tabuchi M, et al. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology. 1992; 42:976-982.
19. The Multicenter Acute Stroke Trial-Europe Study Group. Thrombolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med. 1996; 335:145-150.
20. Donnan GA, Davis SM, McNeil JJ, et al. Letter to editor. Lancet. 1995;345:578.
21. Albers GW, Atkinson, RP, Kelley RE, Rosenbaum DM, for the Dextrorphan Study Group. Safety, tolerability, and pharmacokinetics of the N-methyl-D-aspartate antagonist dextrorphan in patients with acute stroke. Stroke. 1995;26:254-258.
22. Grotta JC, Clark W, Coull B, et al. Safety and tolerability of the glutamate antagonist CGS 19755 (selfotel) in patients with acute ischemic stroke. Stroke. 1995;26:602-605.
23. Clark WM, Coull BM, for the CGS 19755 Study Group. Randomized trial of CGS 19755, a glutamate antagonist, in acute ischemic stroke treatment. Neurology. 1994;44:270. Abstract.
24. Diener H, Hacke W, Hennerici M, Radberg J, Hantson L, Keyser J, for the Lubeluzole International Study Group. Lubeluzole in acute ischemic stroke. Stroke. 1996;27:76-81.
25. Kay R, Wong KS, Yu YL, et al. Low-molecular-weight heparin for the treatment of acute ischemic stroke. N Engl J Med. 1995;333:1588-1593.